Karen Zaderej, Chairman, CEO, and President at Axogen Inc. discusses the development and commercialization of technologies for peripheral nerve regeneration and repair that can restore nerve function and quality of life to patients using innovative, clinically proven, and economically effective solutions. This allows clinicians to repair damaged nerves more efficiently than current standard-of-care procedures, with fewer potential […]

Athira Pharma, Inc will initiate an open-label extension study for two ongoing clinical trials investigating ATH-1017 to treat Alzheimer’s disease. Both clinical trials — the Phase 2/3 LIFT-AD (NCT04488419) and Phase 2 ACT-AD (NCT04491006) — are investigating ATH-1017, a small molecule designed to enhance the effect of hepatocyte growth factor (HGF), and its receptor, MET. Both are expressed in the central nervous system. […]

The advent and evolution of stem cell technology has transformed what is understood about human biology and disease. The biomolecular characterization of stem cells, and their ability to produce virtually any cell in the body revealed new mechanisms of early human development. Beyond their contribution to basic sciences, they show significant promise in the field […]